
Available online at www.sciencedirect.com

Pharmacology & Therapeutics 104 (2004) 47–58

Associate editor: A.L. Morrow

**The gene transcription factor cyclic AMP-responsive element binding protein: role in positive and negative affective states of alcohol addiction**

Subhash C. Pandey*

Department of Psychiatry, Anatomy, and Cell Biology, University of Illinois at Chicago, and Jesse Brown VA Medical Center,  
820 South Damen Avenue (M/C 151), Chicago, IL 60612, United States

---

### Abstract

The gene transcription factor cAMP-responsive element binding (CREB) protein is a nuclear protein that regulates synaptic plasticity via modulating the expression of several cyclic adenosine monophosphate (cAMP)-inducible genes. Alcohol addiction is a complex psychiatric disorder and is characterized by a compulsive and uncontrolled pattern of alcohol drinking by an individual in spite of the adverse consequences of its abuse. Ethanol produces both euphoric (reward and reinforcing) and dysphoric (negative withdrawal reactions) effects and these are most likely involved in the initiation and maintenance of alcohol use and abuse. Several neurotransmitter systems in the brain might be involved in the effects of alcohol but the exact molecular mechanisms of both the positive and negative affective states of alcohol abuse are still unclear. Recent research in molecular neurosciences using animal models have identified the role of extended amygdaloid (shell structures of nucleus accumbens (NAc) and central and medial amygdaloid nuclei) CREB signaling in positive and negative affective states of alcohol drinking behaviors. This review article highlights the current findings on the role of nucleus accumbal and amygdaloid CREB signaling in behavioral consequences of alcohol use and abuse.

© 2004 Elsevier Inc. All rights reserved.

#### Keywords: cAMP; CREB; Brain; Alcohol addiction; Ethanol

#### Abbreviations: AC, adenylate cyclase; BDNF, brain derived neurotrophic factor; CaM, calmodulin; CaM K, CaM kinase; CaM KK, CaM kinase kinase; cAMP, 3′5′ cyclic adenosine monophosphate; CBP, CREB binding protein; CeA, central nucleus of amygdala; CRE, cyclic AMP-responsive element; CRF, corticotropin releasing factor; CREB, cyclic AMP-responsive element binding protein; EA, extended amygdala; Gᵢ, inhibitory guanine nucleotide protein; Gₛ, stimulatory guanine nucleotide protein; MAPK, mitogen activated protein kinase; MeA, medial nucleus of amygdala; MEK, ERK-activating kinase; NAc, nucleus accumbens; NPY, neuropeptide Y; p-CREB, phosphorylated CREB (serine-133); PKA, protein kinase A; PKC, protein kinase C; PLC-β, phospholipase C-β; PTK, protein tyrosine kinase; Ras-GRF, Ras guanine nucleotide releasing factor; RSK, ribosomal S6 kinase; VTA, ventral tegmental area.

---

### Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. Cyclic AMP-responsive element binding protein as a therapeutic target to treat alcoholism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .dysphoric reaction of alcohol withdrawal (Koob, 2003a, 2003b). The cessation of chronic ethanol consumption is often accompanied by withdrawal symptoms indicative of a hyperexcitable state, such as increased anxiety, risk of convulsions, and/or tremors (Koob & Bloom, 1988; Harris & Buck, 1990; Schuckit & Hasselbrock, 1994; Pandey, 2003). Dysphoric reactions, such as anxiety, are a common early symptom of ethanol withdrawal and are considered an important factor in the continued use of alcohol by alcoholics, in that they drink alcohol to alleviate the negative affective states associated with withdrawal (Wilson, 1988; Kushner et al., 1990; Koob et al., 1993; Rassnick et al., 1993; Pandey, 2003; Koob, 2003a). This negative affective state is also responsible for relapse to alcohol use and abuse (Koob, 2003a, 2003b). Thus both dysphoric and euphoric properties of ethanol may promote and maintain the process of alcohol addiction (Fig. 1). Several neurochemical studies in the field have shown that changes in the function of gamma-aminobutyric acid (GABA), glutamate, and corticotrophin-releasing factor (CRF) systems along with other neurotransmitter systems such serotonin and dopamine in brain structures may play a role in the euphoric and dysphoric properties of alcohol (Koob et al., 1998; Koob, 2003a; Kumar et al., 2004).

Current molecular research has also identified some new mechanisms in the specific neural circuitry of the EA that may be involved in the regulation of both positive and negative affective states of alcohol addiction and thus offer further insights into underpinning the cellular mechanisms of alcohol addiction. One such mechanism might involve the c-AMP-responsive element binding (CREB) protein because of its role in adaptational mechanisms in the NAc and amygdala during ethanol exposure and withdrawal as well as in genetic predisposition to alcohol drinking behaviors (Pandey et al., 1999a; Misra et al., 2001; Li et al., 2003; Misra & Pandey, 2003; Pandey et al., 2003a, 2004; Zhang & Pandey, 2003).

project to the posterior medial ventral pallidum, medial VTA, reticular formation, raphe nuclei, and lateral hypothalamus brain structures (Heimer & Alheid, 1991).

Heimer et al. (1991, 1997) proposed that the caudate putamen, accumbens, and the striatal parts of the olfactory tubercle together represent the ventral striatal complex in which the accumbens is considered a prominent component. The NAc is not a homogeneous structure but consists of shell and core structures (Zahm & Brog, 1992; Zahm, 1999, 2000). The shell of NAc is implicated in the reward and motivational aspects of alcohol drinking behaviors (Koob, 2003a, 2003b). The core structures of NAc are linked to the caudate putamen and substantia nigra and are often associated with motor behaviors (Heimer et al., 1991, 1997; Zahm & Brog, 1992; Kalivas et al., 1999).

The central and medial amygdaloid nuclei have been implicated in the negative affective state and motivation associated with excessive alcohol drinking (Koob, 2003a, 2003b). A set of afferent pathways from these amygdaloid nuclei project to anatomical targets in hypothalamus, midbrain, and lower brain stem. These anatomical targets are important in the modulation of visceral functions in relation to emotional stimuli (Price, 2003). There are also several connections among the components of EA, more specifically in between the central nucleus of amygdala (CeA) and the BNST (Heimer & Alheid, 1991; Alheid et al., 1995) and these connections are important in understanding the neuroanatomy of fear and anxiety-like behaviors (Davis & Shi, 1999; Walker et al., 2003). Thus neuroanatomical relationship between the components of EA provided a basis for reinforcing, rewarding, and motivational properties of drugs of abuse in general and ethanol in particular.

### 3. Regulation of cyclic AMP-responsive element binding protein function

Signal transduction triggers by Ca²⁺, cAMP, neurotrophic factors, or other cell stimuli represent complex networks of biochemical processes that ultimately culminate in specific patterns of nuclear gene expression mediated via activation or inhibition of the CREB gene transcription factor (Fig. 2). Thus CREB occupies a central position and represents a convergence point for the interaction of several intracellular signaling cascades (Shieh et al., 1998; Silva et al., 1998; Impey et al., 1999; Mellstrom & Naranjo, 2001; Lonze & Ginty, 2002). CREB is regulated via phosphorylation at serine-133. The CREB protein contains several functional domains. The C-terminal basic domain facilitates DNA binding and the leucine zipper domain facilitates dimerization with CREB or other members of the CREB family such as cAMP response element modulator (CREM) and activating transcription factor 1 (ATF-1) proteins. Another important CREB domain is the kinase inducible domain (KID) that contains the critical serine-133 amino acid residue (Silva et al., 1998; Mayr & Montminy, 2001; Lonze &

### 2. Extended amygdala: an important circuitry for reward, motivation, and reinforcement

The EA was originally described by Johnston (1923) and consists of the bed nucleus of the stria terminalis (BNST), central and medial amygdala, shell of NAc, and sublenticular substantia innominata. The EA anatomically has been divided into two major divisions; the central division and medial division. The central division of EA includes the central nucleus of the amygdala, the central sublenticular EA, lateral BNST, and the medial portions of NAc and olfactory tubercle. The medial division of the EA includes medial BNST, medial nucleus of the amygdala, the medial sublenticular EA (Alheid et al., 1995; Koob, 2003a). Afferent pathways to the EA include frontal, entorhinal, and olfactory cortices, hippocampus, basolateral amygdala, thalamic nuclei, VTA, ventral pallidum, lateral hypothalamus, and lateral septum. The efferent pathways from EA
Fig. 2. Regulation of CREB function by several signaling pathways. The signals triggered by modulation of G-protein coupled receptors (GPCR), voltage gated calcium channels (VGCC), receptors for tyrosine kinases (RTK), or N-methyl-D-aspartate (NMDA) leads to alteration in the function of several protein kinases, namely protein kinase A (PKA), extracellular regulated kinases (ERK1/2), P38 mitogen activated protein kinase (MAPK), and calmodulin kinases (CaM K). All these kinases cause the activation of CREB via phosphorylation at serine-133. The phosphorylation status of CREB is also regulated by dephosphorylation mechanisms. Phosphorylated CREB interacts with CREB binding protein (CBP) and regulates the transcription of genes. Alcohol produces diverse effects on signaling systems to regulate the synaptic plasticity that may be involved in euphoric and dysphoric properties of alcohol.

Ginty, 2002). This residue is phosphorylated by cAMP-dependent protein kinase A (PKA), and Ca²⁺/calmodulin-dependent protein kinases II and IV ((CaMK II and IV) Silva et al., 1998; Soderling, 1999; Mayr & Montminy, 2001; Lonze & Ginty, 2002). CREB phosphorylation at serine-133 is also regulated by ribosomal S₆ kinases (RSK) and CREB kinases (MSK) via activation of a bifurcated pathway from Ras to extracellular regulated kinases (ERK1/2) and p38 MAPK (Xing et al., 1998; Impey et al., 1999). The phosphorylation status of CREB is also regulated via dephosphorylation by activation of several phosphatases including calcineurin (Bito et al., 1996; Tokuda & Hatase, 1998; Groth et al., 2003). Phosphorylated CREB (p-CREB) interacts with CREB binding protein (CBP) and regulates the expression of downstream cAMP-inducible genes (Silva et al., 1998; Lonze & Ginty, 2002).

### 3.1. Cyclic AMP-responsive element binding protein and euphoric (positive affective state) effects of alcohol

The NAc has been associated with rewarding and reinforcing effects of drugs of abuse including ethanol (Robbins & Everitt, 1996; Koob et al., 1998; Koob, 2000, 2003a, 2003b; Hyman & Malenka, 2001; Chao & Nestler, 2004). Rats are known to self-administer a variety of drugs of abuse, including alcohol, into the NAc shell (Wise, 1996; McBride et al., 1999; Rodd-Henricks et al., 2002). Furthermore, drugs of abuse have the property of releasing dopamine in the shell but not in the core of NAc (Imperato & Di Chiara, 1986; Weiss et al., 1993; Zocchi et al., 2003). Ethanol can modulate the function of several signaling systems either at the receptor level, second messenger level, or at the gene expression level (Hoffman & Tabakoff, 1990; Diamond &

S.C. Pandey / Pharmacology & Therapeutics 104 (2004) 47–58

& Tabakoff, 1990; Wand & Levine, 1991; Yang et al., 1996). It has also been shown that chronic ethanol exposure is associated with decreased CRE-DNA binding activity and decreased phosphorylation of CREB in the rat striatum and in the granule cells of the cerebellum (Yang et al., 1998a, 1998b). These earlier studies indicate that neuroadaptive changes occur in cAMP second messenger pathways in the brain structures during chronic ethanol exposure. However, it is only during recent years that some studies have examined the effects of chronic ethanol exposure on CREB function in the reward circuitry in rats.

Chronic voluntary ethanol exposure using the two-bottle free choice paradigm significantly decreases the protein levels of CaMK IV and p-CREB in the shell but not the core of the NAc or other brain structures of rats (Misra et al., 2001). Other investigators have also found that CREB phosphorylation is decreased in the NAc during voluntary ethanol exposure and remain decreased up to 72 hr of ethanol withdrawal (Li et al., 2003). The total CREB protein levels were not altered in the NAc structures by chronic voluntary ethanol exposure in rats (Misra et al., 2001; Li et al., 2003). It has been shown that acute ethanol increases the protein levels of CaMK IV and CREB phosphorylation, but not the total CREB protein levels in the striatum (Yang et al., 1998b). These results suggest the possibility that plasticity associated with neuroadaptation in the shell of NAc during voluntary alcohol exposure may depend upon decreased CaMK IV-dependent CREB phosphorylation that may promote drinking. These molecular changes in the shell of NAc might also be involved in habit formation towards drinking. If the decreased CREB phosphorylation in the shell of NAc is causally responsible for higher alcohol intake, then decreasing the phosphorylation status of CREB in this structure may promote alcohol drinking. This notion was tested by infusion of the PKA inhibitor (Rp-cAMP) into the shell of NAc, and it was found that this pharmacological manipulation significantly decreased the CREB phosphorylation in the shell but not in core structures of NAc. Behaviorally, these rats have a higher preference to alcohol but do not display anxiety-like behaviors (K. Misra and S.C. Pandey, unpublished observations). Furthermore, it was found that basal CREB expression and phosphorylation are lower in the shell structures of the NAc but not in other brain structures of C57BL/6 as compared with DBA/2 mice (Misra & Pandey, 2003). On the other hand, C57BL/6 mice do not display higher anxiety-like behaviors but consume higher amounts of alcohol compared with DBA/2 mice (Misra & Pandey, 2003). Other investigators also have shown that C57BL/6 mice do not display anxiety-like behaviors but have higher preference for alcohol as compared with DBA/2 mice (Belknap et al., 1993; Meliska et al., 1995; Podhorna & Brown, 2002). Furthermore, ethanol-induced excitation of VTA dopaminergic neurons are lower in C57BL/6 mice compared with DBA/2 mice (Brodie & Appel, 2000). These results suggest that C57BL/6 mice or animals with lower CREB in the shell of NAc may

have to drink higher amounts of ethanol to receive the reward related to drinking. Taken together, these results suggest the possibility that decreased CREB function in the NAc may be involved in increased preference to ethanol due to abnormal reward mechanisms.

The role of nucleus accumbal CREB in negative affective states is less clear. For example, over-expression, but not the decreased expression, of CREB in the NAc (shell structures) increases dysphoric and depression-like behaviors in rats (Pliakas et al., 2001; Nestler et al., 2002; Newton et al., 2002). On the other hand, decrease function of CREB in the shell of NAc increases anxiety-like behaviors in rats (Barrot et al., 2002). Further studies are needed to clarify the role of nucleus accumbal CREB in dysphoric or anxiety-like behaviors.

### 3.2. Cyclic AMP-responsive element binding protein and dysphoric (negative affective state) effects of alcohol

Both clinical and epidemiological studies have shown that individuals who are anxious show a greater vulnerability to alcohol abuse (Bibb & Chambless, 1986; Wilson, 1988; Koob, 2003a). On the other hand, alcohol withdrawal also produces anxiety behaviors in alcoholics and animal models (Roelofs, 1985; Wilson, 1988; Baldwin et al., 1991; Lal et al., 1993; Rassnick et al., 1993; Pandey et al., 1999b, 2003a). As mentioned above, amygdaloid brain structures, particularly the CeA and medial nucleus of amygdala (MeA), play a crucial role in anxiety and motivational aspects of alcohol drinking behaviors (Davis, 1997; McBride, 2002; Koob, 2003a). Recently, it was found that protein levels of p-CREB and CaMK IV are significantly decreased in the neurocircuitry of several cortical and amygdaloid (CeA and MeA) brain structures during ethanol withdrawal (24 hr) in rats chronically treated with ethanol (Pandey et al., 2001b; Pandey et al., 2003a). It is interesting to point out that ethanol treated rats also display anxiety-like behaviors at 24 hr of ethanol withdrawal. The infusion of the PKA activator (Sp-cAMP) but not an inhibitor (Rp-cAMP) into the central amygdala during ethanol withdrawal significantly normalized decreased CREB phosphorylation and also blocked ethanol-withdrawal related anxiety (Pandey et al., 2003a). On the other hand, PKA inhibitor (Rp-cAMP) infusion into the central amygdala decreased CREB phosphorylation and provoked anxiety and also increased the alcohol preference in normal rats, thus an effect that mimics ethanol withdrawal (Pandey et al., 2003a). These pharmacological studies are supported by genetic studies, where PKA regulatory subunit (RII-β) mutant mice display high anxiety-like behaviors and also have higher preference to ethanol (Thiele et al., 2000; Fee et al., 2003). Other studies also indicate that genetic manipulations of cAMP-PKA pathway alter alcohol consumption in the animal model (Wand et al., 2001; Yao et al., 2002). Taken together, the evidence accumulated suggests that decreased CREB phosphorylation in the CeA may be involved in anxiety during ethanol withdrawal, and may be

responsible for the maintenance of alcohol intake during ethanol withdrawal. Thus molecular mechanisms associated with negative affective states during ethanol withdrawal might involve decreased CREB function in the neurocircuitry of CeA (Fig. 1).

In recent years, several pieces of evidence have accumulated which suggests that CREB also plays a role in innate anxiety levels (pre-existing negative affective state), which is also a very important factor for the initiation of alcohol drinking behaviors in alcoholics and animal models (Bibb & Chambless, 1986; Spanagel et al., 1995; Koob, 2003a). Thus negative affective states may not only be involved in the maintenance of alcohol addiction but also in the initiation of alcohol drinking behaviors, particularly in those individuals suffering from anxiety disorders (Cappell & Herman, 1972; Bibb & Chambless, 1986; Koob, 2003a; Pandey, 2003). Several lines of evidence indicate that decreased CREB function in the CeA and MeA might be involved in these aspects of alcoholism. The CREB expression and phosphorylation are lower in the amygdala, particularly in the central and medial but not in the basolateral amygdala of alcohol preferring (P) compared with non-prefering (NP) rats (Pandey et al., 1999a, 2003b). Voluntary ethanol intake significantly increased CREB phosphorylation and neuropeptide Y (NPY) expression in the central and medial, but not in the basolateral amygdala while also decreasing anxiety-like behaviors in P rats (S.C. Pandey et al., unpublished observations). Additionally, it has been shown that P rats display more anxiety-like behaviors and consume higher levels of ethanol than NP rats (Li et al., 1993; Stewart et al., 1993).

Recently, the direct role of CREB in anxiety and alcohol drinking behaviors has been demonstrated. CREB mutant mice, which are deficient in transcriptionally active α and Δ CREB isoforms, display more anxiety-like behaviors than wild-type mice (Graves et al., 2002; Pandey et al., 2004; Valverde et al., 2004). More recently using CREB conditional knock out mice it has been shown that decreased CREB levels in the brain are directly involved in anxiety-like behaviors (Valverde et al., 2004). It was found that CREB-α and Δ haplodeficient (+/-) mice have decreased protein levels of CREB and p-CREB in several brain regions including amygdaloid and NAc as compared with wild type mice. The CREB-haplodeficient mice have higher base line anxiety-like behaviors and also have a higher preference to ethanol compared to their wild type littermates (Pandey et al., 2004). Interestingly, acute ethanol exposure produces anxiolytic effects in wild-type mice and this effect is attenuated in CREB-haplodeficient mice. Acute ethanol exposure significantly increased p-CREB protein levels in the central and medial but not in basolateral amygdala. The ethanol exposure tended to increase but not completely normalized the p-CREB protein levels in central and medial amygdala of CREB-deficient mice. These results suggest that the anxiolytic action of ethanol might be mediated via the activation of CREB in amygdaloid brain structures.

These results also suggest the possibility that CREB-haplodeficient mice may have higher anxiety levels due to lower CREB levels in the CeA and MeA and that they drink more ethanol to self medicate their higher levels of anxiety-like behaviors (Pandey et al., 2004). It has been shown that increased CREB function in the shell of NAc is associated with a dysphoric state and also produces depression-like effects in rats (Nestler et al., 2002; Pliakas et al., 2001). On the other hand, decreased CREB function in the amygdala is associated with anxiety-like effects in rats (Pandey et al., 2003a, 2004). In light of these data, it can be suggested that decreased CREB function in the NAc may be involved in reward mechanisms (positive affective state) and in the CeA and MeA may be involved in negative affective state of alcohol addiction (Fig. 1). This hypothesis needs to be tested further in future studies to identify the differential role of CREB in different neurocircuitry of the EA.

### 3.3. Cyclic AMP-responsive element binding protein and other effects of alcohol

It has been shown that individuals who are less sensitive to the sedative and hypnotic effects of ethanol are at high risk to develop alcoholism (Schuckit, 1994; Schuckit & Smith, 2000). Several studies have examined the role of cAMP second messenger pathway in sedative effects of ethanol in animal and *Drosophila* models. It has been shown that genetic or pharmacological manipulation, which decreases or increases the function of PKA in *Drosophila*, makes these flies more or less sensitive to ethanol, respectively (Moore et al., 1998; Rodan et al., 2002). Studies show that a significant genetic correlation exists between ethanol-induced sleep time and ethanol sensitivity of Purkinje cells in the cerebellum. It has been shown that cAMP signaling modulates the inhibition of Purkinje cells by ethanol and acute ethanol increases CREB phosphorylation in the cerebellum (Spuhler et al., 1982; Freund & Palmer, 1997; Yang et al., 1998a). Recently, Wand and his coworkers reported that mice with targeted disruption of one Gsα allele fail to develop tolerance to the sedative effects of ethanol and this may be related to lack of ability of ethanol to increase the CREB phosphorylation in the cerebellum, hippocampus, and frontal cortex (Yang et al., 2003). Furthermore, PKA-mutant mice and *Drosophila* with a mutation in the PKA-RII gene were found to be less sensitive to the sedative effects of ethanol (Park et al., 2000; Thiele et al., 2000). Other investigators found a significant correlation between isoproterenol and forskolin stimulated cAMP accumulation in the cerebellar brain regions and ethanol’s ataxic effects (Kirstein & Tabakoff, 2001). These results collectively suggest that the cAMP second messenger pathway is also important in ethanol-induced sedation.

CREB has recently been implicated in ethanol withdrawal-induced neuronal hyperexcitability in the hippocampal structures of rats. Bison and Crews (2003) have shown that ethanol withdrawal induced seizures are

associated with drastic increases in NPY and p-CREB immunoreactivity in the dentate gyrus of rats. Since NPY and CREB in the brain have been implicated in seizure activity (Ishige et al., 1996; Woldbye, 1998), these authors suggested that increases in NPY and p-CREB during withdrawal after binge alcohol might play a role in the protective action against ethanol withdrawal related seizures (Bison & Crews, 2003). Taken together, these results suggest that CREB in different neurocircuits plays a role in a myriad of behavioral effects associated with ethanol exposure and withdrawal.

### 3.4. Cyclic AMP-responsive element binding protein target genes and ethanol effects

The CREB gene transcription factor has been shown to regulate the expression of several cAMP-inducible genes, such as enkephalin, dynorphin, CRF, brain derived neurotrophic factor (BDNF), and NPY (Itoi et al., 1996; Carlezon et al., 1998; Mayr & Montminy, 2001; McClung & Nestler, 2003; Pandey, 2003; Pandey et al., 2004). NPY is a neuromodulator and plays an important role in anxiety as well as alcohol preference and dependence (Heilig et al., 1993; Thiele et al., 1998; Hwang et al., 1999; Roy & Pandey, 2002; Thorsell & Heilig, 2002). Decreased NPY function in the CeA is involved in anxiety-like behaviors (Heilig et al., 1993) and NPY mutant mice also display anxiety-like behaviors and have a higher preference to ethanol (Palmiter et al., 1998; Thiele et al., 1998). Recently, it has been shown that decreased CREB phosphorylation in the CeA regulates anxiety and alcohol-drinking behaviors via NPY in rats (Pandey et al., 2003a, 2003b). It was recently found that protein levels of NPY are lower in the shell structure of the NAc of C57BL/6 compared to DBA/2 mice (Misra & Pandey, 2003). Furthermore, decreased CREB phosphorylation in the CeA and MeA are associated with decreased expression of NPY during ethanol withdrawal in rats (Roy & Pandey, 2002). Pharmacological normalization of CREB phosphorylation in the CeA during ethanol withdrawal also normalizes the expression of NPY and prevents the development of anxiety-like behaviors in rats (Pandey et al., 2003a; Zhang & Pandey, 2003). It has also been shown that intra-brain infusion of NPY prevents the negative reactions of ethanol withdrawal in rats (Woldbye et al., 2002). More recently, it has been shown that CREB-haplodeficient mice are deficient in the expression of NPY and BDNF in various brain structures including NAc and amygdala, and consume high amounts of alcohol (Pandey et al., 2004). It was also found that NPY knockout mice drink high amounts of alcohol, whereas mice over-expressing NPY have a lower alcohol preference (Thiele et al., 1998).

Recently, it has been shown that the BDNF gene is involved in alcohol abuse (Uhl et al., 2001) and BDNF-haplodeficient mice also have a higher preference for ethanol (Hensler et al., 2003). Furthermore, BDNF condi-

functional knock out mice are more prone to anxiety-like behaviors (Rios et al., 2001). Taken together, these results suggest that CREB may regulate anxiety and alcohol drinking behaviors via regulating the expression of NPY and BDNF or several other genes whose expressions are regulated by CREB (Mayr & Montminy, 2001; McClung & Nestler, 2003).

The corticotropin releasing factor (CRF) is a 41 amino acid polypeptide that is regulated by CREB (Swanson et al., 1983; Itoi et al., 1996). This peptide is highly distributed throughout the brain and very abundant in the EA (Swanson et al., 1983; Koob, 2003a). The increases in the levels of CRF are found in the CeA and BNST in rats during ethanol withdrawal after chronic exposure (Merlo-Pich et al., 1995; Olive et al., 2002). It was found that infusion of CRF receptor-2 agonist (urocortin 3) directly into the brain is able to prevent anxiety-like behaviors and also alcohol self-administration in rats (Valdez et al., 2004). Interestingly, CRF-2 receptor mutant mice exhibit increased anxiety-like behaviors and this is most likely related to decreased CREB phosphorylation in the brain areas associated with emotional and autonomic function (Kishimoto et al., 2000). These results suggest the possibility that decreased CRF-2 receptors function (decreased CREB phosphorylation) may be operative in the EA in regulating the negative affective state associated with alcohol addiction.

It is not clear how CREB may regulate alcohol reward mechanisms in the NAc. Nestler and his colleagues have shown that CREB, via changing the expression of the dynorphin gene in the NAc, participate in the regulation of reward related to drugs of abuse (Carlezon et al., 1998; Nestler, 2001). The relationship between CREB and dynorphin gene expression in the NAc is less clear during alcohol drinking behaviors. Dynorphin levels are lower or normal in the NAc of alcohol preferring compared to alcohol avoiding rats (Nylander et al., 1994; Fadda et al., 1999). Brown et al. (2000) observed that NPY, another CREB target gene, in the NAc is rewarding in rats. Moreover, Olive et al. (2003) have observed that a CRF deficiency might lead to excessive ethanol consumption by reducing the rewarding effects of ethanol. Thus, another possibility is that CREB may regulate alcohol reward by modulating the expression of NPY or CRF in the NAc. Future studies are needed to explore if CREB regulates alcohol reward mechanisms in part by modulating the expressions of dynorphin and NPY genes or other CREB related genes such as BDNF or CRF in the NAc.

### 4. Cyclic AMP-responsive element binding protein as a therapeutic target to treat alcoholism

Several antidepressant drugs have been shown to be effective in treating alcoholism (Lejoyeux, 1996; Pettinati, 1996). For example, the 5HT-uptake blocker (fluoxetine)
and other antidepressants are effective in preventing drinking in some alcoholics (Pettinati et al., 2003). Accumulating evidence also indicates that 5HT-uptake blockers are clinically effective in treating some forms of anxiety disorders (Nardi, 2001; Williams & Miller, 2003). Thus the primary action of fluoxetine may be mediated via the serotonergic system; however, long-term treatment may lead to adaptations in specific neurocircuitry via changes in the expression and activity of the CREB transcription factor (Duman, 1998). Chronic fluoxetine treatment increases the expression and phosphorylation of CREB and CRE-mediated gene transcription in various brain structures of rodents, including the amygdaloid structures (Duman, 1998; Thome et al., 2000b; D'Sa & Duman, 2002). It has also been shown that chronic treatment with fluoxetine and mianserin attenuates the anxiety-like behaviors in rats during ethanol withdrawal (Lal et al., 1993; Pandey et al., 1999b).

There are at least two possibilities to suggest why fluoxetine is effective in treating alcohol dependence: (a) anxiety and depression are common symptoms of ethanol withdrawal and these symptoms may be prevented by fluoxetine treatment; (b) anxiety may be developing during alcohol withdrawal via decreased function of CREB signaling in the CeA and MeA and fluoxetine treatment may increase the CREB phosphorylation and CREB related target gene in the amygdala. These possibilities suggest that CREB may act as a common molecular switch for the actions of ethanol and antidepressant drugs on negative affective states of addiction. It was also found that chronic ethanol treatment and its withdrawal are associated with decreased CREB phosphorylation in the NAc and that these changes are reversed by treatment with mianserin or with naloxone in rats (Misra et al., 2001; Li et al., 2003). These drugs are also effective in attenuating the alcohol intake in animal models as well as in alcoholics (Overstreet et al., 1997, 1999; Misra et al., 2001; Kranzler et al., 2003). These results suggest that drugs which have the ability to increase the function of CREB in the CeA, MeA, and NAc may be beneficial in treating alcohol-related behaviors.

hedonic theory of alcohol addiction, which may be linked to decreased function of CREB in the circuitry of the EA (Fig. 1). Some studies also suggest the possibility that CREB in the circuitry of the cerebellum might be involved in the sedative effects of ethanol and the circuitry of cortex and hippocampus might be associated with withdrawal related seizures. Since CREB is highly implicated in addictive behaviors as well as in depressive and anxiety-like behaviors, it is possible that CREB may act as a common molecular switch for altering the synaptic plasticity associated with alcohol and drug addiction with or without co-morbid depression or anxiety behaviors. Future studies are clearly needed to determine the role of various CREB related genes in several behavioral effects of ethanol and in co-morbidity with depression or anxiety. CREB represents a very unique target for developing new pharmacotherapy because correcting deficits in CREB function can correct the malfunctioning of several CREB related genes in alcoholism.

Acknowledgment

The studies by SCP were supported by grants from the Department of Veterans Affairs (Merit Review Grant) and the National Institute on Alcohol Abuse and Alcoholism (AA10005; AA13341). The author would like to thank Mr. Kaushik Misra for his assistance in the preparation of this manuscript.

References

Alheid, G., de Olmos, J. S., & Beltramino, C. A. (1995). Amygdala and extended amygdala. In G. Paxinas (Ed.), *The Rat Nervous System* (pp. 495–578). New York: Academic Press.

American Psychiatric Association (1994). *Diagnostic and Statistical Manual of Mental Disorders* (4th ed.). Washington, DC: American Psychiatric Press.

Appel, S. B., Liu, Z., McElvain, M. A., & Brodie, M. S. (2003). Ethanol excitation of dopaminergic ventral tegmental area neurons is blocked by quinidine. *J Pharmacol Exp Ther* 306, 437–446.

Baldwin, H. A., Rassnick, S., Rivier, J., Koob, G. F., & Britton, K. T. (1991). CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat. *Psychopharmacology* 103, 227–232.

Barrot, M., Olivier, J. D., Perrotti, L. I., DiLeone, R. J., Berton, O., Eisch, A. J., Impey, S., Storm, D. R., Neve, R. L., Yin, J. C., Zachariou, V., & Nestler, E. J. (2002). CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. *Proc Natl Acad Sci* 99, 11435–11440.

Belknap, J. K., Crabbe, J. C., & Young, E. R. (1993). Voluntary consumption of ethanol in 15 inbred mouse strains. *Psychopharmacology* 112, 503–510.

Bibb, J. L., & Chambless, D. L. (1986). Alcohol use and abuse among diagnosed agoraphobics. *Behav Res Ther* 24, 49–58.

Bison, S., & Crews, F. (2003). Alcohol withdrawal increases neuropeptide Y immunoreactivity in rat brain. *Alcohol Clin Exp Res* 27, 1173–1183.

Bito, H., Deisseroth, K., & Tsein, R. W. (1996). CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression. *Cell* 87, 1203–1214.

5. Conclusions

The evidence discussed here indicates that decreased CREB function in the shell of NAc may be involved in producing positive affective states (reward and reinforcing properties of ethanol) of alcohol use. On the other hand, decreased CREB function in the CeA and MeA may be involved in producing and maintaining negative affective states (anxiety-like withdrawal symptoms) of ethanol withdrawal. It is also possible that decreased CREB function in CeA and MeA structures may be important in the co-morbidity between anxiety and alcohol drinking behaviors. We therefore propose a molecular model for the
Brodie, M. S., & Appel, S. B. (2000). Dopaminergic neurons in the ventral tegmental area of C57BL/6J and DBA/2J mice differ in sensitivity to ethanol excitation. *Alcohol Clin Exp Res* 24, 1120–1124.

Brown, C. M., Coscina, D. V., & Fletcher, P. J. (2000). The rewarding properties of neuropeptide Y in perifornical hypothalamus vs. nucleus accumbens. *Peptides* 21, 1279–1287.

Cappell, H., & Herman, C. P. (1972). Alcohol and tension reduction. A review. *Q J Stud Alcohol* 33, 33–64.

Carlezon, W. A., Jr., Thome, J., Olson, V. G., Lane-Ladd, S. B., Brodkin, E. S., Hiroi, N., Duman, R. S., Nerve, R. L., & Nestler, E. J. (1998). Regulation of cocaine reward by CREB. *Science* 282, 2272–2275.

Chao, J., & Nestler, E. J. (2004). Molecular neurobiology of drug addiction. *Annu Rev Med* 55, 113–132.

Cloninger, C. R. (1987). Neurogenetic adaptive mechanisms in alcoholism. *Science* 236, 410–416.

Davis, M. (1997). Neurobiology of fear responses: the role of the amygdala. *J Neuropsychiatry Clin Neurosci* 9, 382–402.

Davis, M., & Shi, C. (1999). The extended amygdala: are the central nucleus of amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? *Ann N Y Acad Sci* 877, 281–291.

Diamond, I., & Gordon, A. (1997). Cellular and molecular neuroscience of alcoholism. *Physiol Rev* 77, 1–20.

D'Sa, C., & Duman, R. S. (2002). Antidepressants and neuroplasticity. *Bipolar Disord* 4, 183–194.

Duman, R. S. (1998). Novel therapeutic approaches beyond the serotonin receptor. *Biol Psychiatry* 44, 324–335.

Enoch, M. A. (2003). Pharmacogenomics of alcohol response and addiction. *Am J Pharmacogenomics* 3, 217–232.

Fadda, P., Tronci, S., Colombo, G., & Fratta, W. (1999). Differences in the opioid system in selected brain regions of alcohol-prefering and non-prefering rats. *Alcohol Clin Exp Res* 23, 1296–1305.

Fee, J. R., Sparta, D. R., & Thiele, T. E. (2003). High ethanol consumption in protein kinase A mutant mice is correlated with high basal anxiety. *Alcohol Exp Clin Res* 27, 51A (supplement).

Freund, R. K., & Palmer, M. R. (1997). Beta adrenergic sensitization of gamma-aminobutyric acid receptors to ethanol involves a cyclic AMP/ Protein kinase A second messenger mechanism. *J Pharmacol Exp Ther* 280, 1192–2000.

Graves, L., Dalvi, A., Lucki, I., Blendy, J. A., & Abel, T. (2002). Behavioral analysis of CREB α Δ mutation on B6/129 F1 background. *Hippocampus* 12, 18–26.

Groth, R. D., Dunbar, R. L., & Mermelstein, P. G. (2003). Calcineurin regulation of neuronal plasticity. *Biochem Biophys Res Commun* 311, 1159–1571.

Harris, R. A., & Buck, K. J. (1990). The process of alcohol tolerance and dependence. *Alcohol World Health Res* 14, 105–110.

Heimer, L., & Alheid, G. F. (1991). Piecing together the puzzle of basal forebrain anatomy. *Adv Exp Med Biol* 295, 1–42.

Heimer, L., Alheid, G. F., de Olmos, J. S., Groenewegen, H. J., Haber, S. N., Harlan, R. E., & Zahm, D. S. (1997). The accumbens: beyond the core-shell dichotomy. *J Neuropsychol* 9, 354–381.

Heimer, L., Zahm, D. S., Churchill, L., Kalivas, P. W., & Wohlmann, C. (1991). Specificity in the projection patterns of accumbal core and shell in the rat. *Neuroscience* 41, 89–125.

Heilig, M., McLeod, S., Brot, M., Heinrichs, S. C., Menzaghi, F., Koob, G. F., & Britton, K. T. (1993). Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. *Neuropsychopharmacology* 8, 357–363.

Hensler, J. G., Ladenheim, E. E., & Lyons, W. E. (2003). Ethanol consumption and serotonin-1A (5-HT1A) receptor function in heterozygous BDNF (+/-) mice. *J Neurochem* 85, 1139–1147.

Hoffman, P. L., & Tabakoff, B. (1990). Ethanol and guanine nucleotide binding proteins: a selective interaction. *Fed Am Soc Exp Biol J* 4, 2612–2622.

Hwang, B. H., Zhang, J. -K., Ehlers, C. L., Lumeng, L., & Li, T. -K. (1999). Innate differences of neuropeptide Y (NPY) in hypothalamic nuclei and central nucleus of the amygdala between selectively bred rats with high and low alcohol preference. *Alcohol Clin Exp Res* 23, 1023–1030.

Hyman, S. E. (1995). A man with alcoholism and HIV infection. *J Am Med Assoc* 274, 837–843.

Hyman, S. E., & Malenka, R. C. (2001). Addiction and the brain: the neurobiology of compulsion and its persistence. *Nat Rev Neurosci* 2, 695–703.

Imperato, A., & Di Chiara, G. (1986). Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. *J Pharmacol Exp Ther* 239, 219–228.

Impey, S., Obrietan, K., & Storm, D. R. (1999). Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. *Neuron* 23, 11–14.

Ishige, K., Aizawa, M., Ito, Y., & Fukuda, H. (1996). γ-Butyrolactone-induced absence-like seizures increase nuclear CRE- and AP-1 DNA binding activity in mouse brain. *Neuropharmacology* 35, 45–55.

Itoi, K., Horiba, N., Tozawa, F., Sakai, Y., Sakai, K., Abe, K., Demura, H., & Suda, T. (1996). Major role of 3′,5′-cyclic adenosine monophosphate-dependent protein kinase A pathway in corticotropin-releasing factor gene expression in the rat hypothalamus in vivo. *Endocrinology* 137, 2389–2396.

Johnston, J. B. (1923). Further contributions to the study of the evaluation of the forebrain. *J Comp Neurol* 35, 337–481.

Kalivas, P. W., Churchill, L., & Romanides, A. (1999). Involvement of the pallidal-thalamocortical circuit in adaptive behavior. *Ann N Y Acad Sci* 877, 64–70.

Kirstein, S. L., & Tabakoff, B. (2001). Genetic correlations between initial sensitivity to ethanol and brain cAMP signaling in inbred and selectively bred mice. *Alcohol Clin Exp Res* 25, 791–799.

Kishimoto, T., Radulovic, J., Radulovic, M., Lin, C. R., Schrick, C., Hooshmano, F., Hermanson, O., Rosenfeld, M. G., & Spiess, J. (2000). Deletion of CRHR2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. *Nat Genet* 24, 415–419.

Knapp, C. M., Foye, M. M., Ciraulo, D. A., & Kornetsky, C. (1999). The type IV phosphodiesterase inhibitors, Ro20-1724 and rolipram, block the initiation of cocaine self-administration. *Pharmacol Biochem Behav* 62, 151–158.

Knapp, C. M., Lee, K., Foye, M., Ciraulo, D. A., & Kornetsky, C. (2001). Additive effects of intra-accumbens infusion of the cAMP specific phosphodiesterase inhibitor, rolipram and cocaine on brain stimulation reward. *Life Sci* 69, 1673–1682.

Koob, G. F. (2000). Neurobiology of addiction. Toward the development of new therapies. *Ann N Y Acad Sci* 909, 170–185.

Koob, G. F. (2003a). Alcoholism: allostasis and beyond. *Alcohol Clin Exp Res* 27, 232–243.

Koob, G. F. (2003b). Neuroadaptive mechanisms of addiction: studies on the extended amygdala. *Eur Neuropsychopharmacol* 13, 442–452.

Koob, G. F., & Bloom, F. E. (1988). Cellular and molecular mechanisms of drug dependence. *Science* 242, 715–723.

Koob, G. F., & Le Moal, M. (1997). Drug abuse: hedonic homeostatic dysregulation. *Science* 278, 52–58.

Koob, G. F., & Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. *Neuropsychopharmacology* 24, 97–129.

Koob, G. F., Markou, A., Weiss, F., & Schulteis, G. (1993). Opponent process and drug dependence: neurobiological mechanisms. *Semin Neurosci* 5, 351–358.

Koob, G. F., Sanna, P. P., & Bloom, F. E. (1998). Neuroscience of addiction. *Neuron* 21, 467–476.

Kranzler, H. R., Armeli, S., Tennen, H., Blomquist, O., Oncken, C., Petry, N., & Feinn, R. (2003). Targeted naltrexone for early problem drinkers. *J Clin Psychopharmacol* 23, 294–304.

Kumar, S., Fleming, R. L., & Morrow, A. L. (2004). Ethanol regulation of γ-aminobutyric acid A<sub>A</sub> receptors: genomic and nongenomic mechanisms. *Pharmacol Ther* 101, 211–226.

Kushner, M. G., Sher, J. K., & Beitmann, B. D. (1990). The relation between alcohol problems and the anxiety disorders. *Am J Psychiatry* 147, 685–695.

Lal, H., Prather, P. L., & Rezazadeh, S. M. (1993). Potential role of 5-HT<sub>1C</sub> and/or 5-HT<sub>2</sub> receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. *Alcohol Clin Exp Res* 17, 411–417.

Lejoyeux, M. (1996). Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. *Alcohol Alcohol* 1, 69–75.

Li, J., Li, Y.-H., & Yuan, X.-R. (2003). Changes of phosphorylation of cAMP response element binding protein in rat nucleus accumbens after chronic ethanol intake: naloxone reversal. *Acta Pharmacol Sin* 24, 930–936.

Li, T.-K., Lumeng, L., & Doolittle, D. P. (1993). Selective breeding for alcohol preference and associated responses. *Behav Genet* 23, 163–170.

Lonze, B. E., & Ginty, D. D. (2002). Function and regulation of CREB family transcription factors in the nervous system. *Neuron* 35, 605–623.

Mayr, B., & Montminy, M. (2001). Transcriptional regulation by the phosphorylation-dependent factor CREB. *Nat Rev Mol Cell Biol* 2, 599–609.

McBride, W. J. (2002). Central nucleus of the amygdala and the effects of alcohol and alcohol-drinking behavior in rodents. *Pharmacol Biochem Behav* 71, 509–515.

McBride, W. J., Bodart, B., Lumeng, L., & Li, T.-K. (1995). Association between low contents of dopamine and serotonin in the nucleus accumbens and high alcohol preference. *Alcohol Clin Exp Res* 19, 1420–1422.

McBride, W. J., Murphy, J. M., & Ikemoto, S. (1999). Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. *Behav Brain Res* 101, 129–152.

McClung, C. A., & Nestler, E. J. (2003). Regulation of gene expression and cocaine reward by CREB and Delta FosB. *Nat Neurosci* 6, 1208–1215.

Meliska, C. J., Bartke, A., McGlacken, G., & Jensen, R. A. (1995). Ethanol, nicotine, amphetamine, and aspartame consumption and preferences in C57BL/6 and DBA/2 mice. *Pharmacol Biochem Behav* 50, 619–626.

Mellstrom, B., & Naranjo, J. R. (2001). Mechanisms of Ca<sup>2+</sup>-dependent transcription. *Curr Opin Neurobiol* 11, 312–319.

Merlo-Pich, E., Lorang, M., Yeganeh, M., Rodriguez de Fonseca, F., Raber, J., Koob, G. F., & Weiss, F. (1995). Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. *J Neurosci* 15, 5439–5447.

Misra, K., & Pandey, S. C. (2003). Differences in basal levels of CREB and NPY in nucleus accumbens regions between C57BL/6 and DBA/2 mice differing in inborn alcohol drinking behavior. *J Neurosci Res* 74, 967–975.

Misra, K., Roy, A., & Pandey, S. C. (2001). Effects of voluntary ethanol intake on the expression of Ca<sup>2+</sup>/calmodulin-dependent protein kinase IV and on CREB expression and phosphorylation in the rat nucleus accumbens. *NeuroReport* 12, 4133–4137.

Moore, R. Y., & Bloom, F. E. (1978). Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. *Annu Rev Neurosci* 1, 129–169.

Moore, M. S., DeZazzo, J., Luk, A. Y., Tully, T., Singh, C. M., & Heberlein, U. (1998). Ethanol intoxication in *Drosophila*: genetic and pharmacological evidence for regulation by the cAMP signaling pathway. *Cell* 93, 997–1007.

Morrow, A. L., Ferrani-Kile, K., Davis, M. I., Shumilla, J. A., Maldve, R., & Pandey, S. C. (2004). Ethanol effects on cell signaling mechanisms. *Alcohol Clin Exp Res* 28, 217–227.

Nardi, A. E. (2001). Antidepressants in social anxiety disorder. *Arq Neuropsiquiatr* 59(3-A), 637–642.

National Institute on Alcohol Abuse and Alcoholism (1993). Eighth Special Report to the Congress on Alcohol and Health. *DHHS Publ ADM 281-91-003*, (Bethesda).

Nestler, E. J. (2001). Molecular basis of long-term plasticity underlying addiction. *Nat Rev Neurosci* 2, 119–128.

Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002). Neurobiology of depression. *Neuron* 34, 13–25.

Newton, S. S., Thome, J., Wallace, T. L., Shirayama, Y., Schlesinger, L., Sakai, N., Chen, J., Neve, R., Nestler, E. J., & Duman, R. S. (2002). Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. *J Neurosci* 22, 10883–10890.

Nylander, I., Hyttia, P., Forsander, O., & Terenius, L. (1994). Differences between alcohol-prefering(AA) and alcohol-avoiding (ANA) rats in the prodynorphin and proenkephalin systems. *Alcohol Clin Exp Res* 18, 1272–1279.

Olive, M. F., Koenig, H. N., Nannini, M. A., & Hogde, C. W. (2002). Elevated extra cellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. *Phrmacol Biochem Behav* 72, 213–220.

Olive, M. F., Mehert, K. K., Koenig, H. N., Camarini, R., Kim, J. A., Nannini, M. A., Ou, C. J., & Hodge, C. W. (2003). A role for corticotropin releasing factor (CRF) in ethanol consumption, sensitivity, and reward as revealed by CRF-deficient mice. *Psychopharmacology* 165, 181–187.

Overstreet, D. H., Kampov-Polvoy, A. B., Rezvani, A. H., Braun, C., Bartus, R. T., & Crews, F. T. (1999). Suppression of alcohol intake by chronic naloxone treatment in P rats: tolerance development and elevation of opiate receptor binding. *Alcohol Clin Exp Res* 23, 1761–1771.

Overstreet, D. H., Mcarthur, R. A., Rezvani, A. H., & Post, C. (1997). Selective inhibition of alcohol intake in diverse alcohol-prefering rat strains by the 5-HT2A antagonists amperozide and FG 5974. *Alcohol Clin Exp Res* 21, 1448–1454.

Palmiter, R. D., Erickson, J. C., Hollopeter, G., Baraban, S. C., & Schwartz, M. W. (1998). Life without neuropeptide Y. *Recent Prog Horm Res* 53, 163–199.

Pandey, S. C. (2003). Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. *TIPS* 24, 456–460.

Pandey, S. C., Mittal, N., Lumeng, L., & Li, T.-K. (1999a). Involvement of the cyclic AMP-responsive element binding protein gene transcription factor in genetic preference for alcohol drinking behavior. *Alcohol Clin Exp Res* 23, 1425–1434.

Pandey, S. C., Zhang, D., Mittal, N., & Nayyar, D. (1999b). Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety. *J Pharmacol. Exp. Ther.* 288, 866–878.

Pandey, S. C., Saito, T., Yoshimura, M., Sohma, H., & Gotz, M. E. (2001a). cAMP signaling cascade: a promising role in ethanol tolerance and dependence. *Alcohol Clin Exp Res* 25, 46S–48S.

Pandey, S. C., Roy, A., & Mittal, N. (2001b). Effects of chronic ethanol intake and its withdrawal on the expression and phosphorylation of the CREB gene transcription factor in rat cortex. *J Pharmacol Exp Ther* 296, 857–868.

Pandey, S. C., Roy, A., & Zhang, H. (2003a). The decreased phosphorylation of cyclic adenosine monophosphate (cAMP) response element binding (CREB) protein in the central amygdala acts as a molecular substrate for anxiety related to ethanol withdrawal in rats. *Alcohol Clin Exp Res* 27, 396–409.

Pandey, S. C., Carr, L. G., Heilig, M., Ilveskoski, E., & Thiele, T. E. (2003b). Neuropeptide Y and alcoholism: genetic, molecular, and pharmacological evidence. *Alcohol Clin Exp Res* 27, 149–154.

Pandey, S. C., Roy, A., Zhang, H., & Xu, T. (2004). Partial deletion of the CREB gene promotes alcohol-drinking behaviors. *J Neurosci* 24, 5022–5030.

Park, S. K., Sedore, S. A., Cronmiller, C., & Hirsh, J. (2000). PKA-RII-deficient *Drosophila* are viable but show developmental, circadian and drug response phenotypes. *J Biol Chem* 275, 20588–20596.

Pettinati, H. M. (1996). Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. *Alcohol Clin Exp Res* 20, 23A–29A.

Pettinati, H. M., Kranzler, H. R., & Madras, J. (2003). The status of serotonin-selective pharmacotherapy in the treatment of alcohol dependence. *Recent Dev Alcohol* 16, 247–262.

Pliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J., & Carlezon, W. A., Jr. (2001). Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. *J Neurosci* 21, 7397–7403.

Podlhorná, J., & Brown, R. E. (2002). Strain differences in activity and emotionality do not account for differences in learning and memory performance between C57BL/6 and DBA/2 mice. *Genes, Brain Behav* 1, 96–110.

Price, J. L. (2003). Comparative aspects of amygdala connectivity. *Ann N Y Acad Sci* 985, 50–58.

Radel, M., & Goldman, D. (2001). Pharmacogenetics of alcohol response and alcoholism: the interplay of genes and environmental factors in thresholds for alcoholism. *Drug Metab Dispos* 29, 489–494.

Rahman, S., & Miles, M. F. (2001). Identification of novel ethanol-sensitive genes by expression profiling. *Pharmacol Ther* 92, 123–134.

Rassnick, S., Heinrichs, S. C., Britton, K. T., & Koob, G. F. (1993). Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. *Brain Res.* 605, 25–32.

Rios, M., Fan, G., Fekete, C., Kelly, J., Bates, B., Kuehn, R., Lechan, R. M., & Jaenisch, R. (2001). Conditional deletion of brain derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. *Mol Endocrinol* 15, 1748–1757.

Robbins, T. W., & Everitt, B. J. (1996). Neurobehavioral mechanisms of reward and motivation. *Curr Opin Neurobiol* 6, 228–236.

Robbins, T. W., & Everitt, B. J. (1999). Drug addiction: bad habits add up. *Nature* 398, 567–570.

Rodan, A. R., Kiger, J. A., Jr., & Heberlein, U. (2002). Functional dissection of neuroanatomical loci regulating ethanol sensitivity in *Drosophila*. *J Neurosci* 22, 9490–9501.

Rodd-Henricks, Z. A., McKinzie, D. L., Li, T. -K., Murphy, J. M., & McBride, W. J. (2002). Cocaine is self-administered into the shell but not core of the nucleus accumbens of Wistar rats. *J Pharmacol Exp Ther* 303, 1216–1226.

Roelofs, S. M. (1985). Hyperventilation, anxiety, craving for alcohol: a subacute alcohol withdrawal syndrome. *Alcohol* 2, 501–505.

Roy, A., & Pandey, S. C. (2002). The decreased cellular expression of neuropeptide Y protein in the rat brain structures during ethanol withdrawal after chronic ethanol exposure. *Alcohol Clin Exp Res* 26, 796–803.

Schuckit, M. A. (1994). Low level of response to alcohol as a predictor of future alcoholism. *Am J Psychiatry* 151, 184–189.

Schuckit, M. A., & Hasselbrock, V. (1994). Alcohol dependence and anxiety disorders: what is the relationship? *Am J Psychiatry* 151, 1723–1734.

Schuckit, M. A., & Smith, T. L. (2000). The relationships of a family history of alcohol dependence, low level of response to alcohol and six domains of life functioning to the development of alcohol use disorders. *J Stud Alcohol* 61, 827–835.

Shieh, P. B., Hu, S. -C., Bobb, K., Timmus, T., & Ghosh, A. (1998). Identification of a signaling pathway involved in calcium regulation of BDNF expression. *Neuron* 20, 727–740.

Silva, A. J., Kogan, J. H., Frankland, P. W., & Kida, S. (1998). CREB and memory. *Annu Rev Neurosci* 21, 127–148.

Soderling, T. R. (1999). The Ca²⁺-calmodulin-dependent protein kinase cascade. *Trends Biochem Sci* 24, 232–236.

Spanagel, R., Montkowski, A., Allingham, K., Stöhr, T., Shoaib, M., Holsboer, F., & Landgraf, R. (1995). Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. *Psychopharmacology* 122, 369–373.

Spuhler, K., Hoffer, B., Weiner, N., & Palmer, M. (1982). Evidence for genetic correlation of hypnotic effects and cerebellar Purkinje neuron depression in response to ethanol in mice. *Pharmacol Biochem Behav* 17, 569–578.

Stewart, R. B., Gatto, G. J., Lumeng, L., Li, T. -K., & Murphy, J. M. (1993). Comparison of alcohol-prefering (P) and non-prefering (NP) rats on tests of anxiety and for the anxiolytic effects of ethanol. *Alcohol* 10, 1–10.

Swanson, L. W., Sawchenko, P. E., Rivier, J., & Vale, W. (1983). The organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. *Neuroendocrinology* 36, 165–186.

Thiele, T. E., Marsh, D. J., Marie, L. S., Berstein, I. L., & Palmiter, R. D. (1998). Ethanol consumption and resistance are inversely related to neuropeptide Y levels. *Nature* 396, 366–369.

Thiele, T. E., Willis, B., Stafler, J., Reynolds, J. G., Bernstein, I. L., & McKnight, G. S. (2000). High ethanol consumption and low sensitivity to ethanol-induced sedation in protein kinase A-mutant mice. *J Neurosci* 20, RC75.

Thome, J., Gewirtz, J. C., Weijers, H. G., Weisbeck, G. A., & Henn, F. A. (2000a). Genome polymorphism and alcoholism. *Pharmacogenomics* 1, 63–71.

Thome, J., Sakai, N., Shin, K., Steffen, C., Zhang, Y. J., Impey, S., Storm, D., & Duman, R. S. (2000b). cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. *J Neurosci* 20, 4030–4036.

Thorsell, A., & Heilig, M. (2002). Diverse functions of neuropeptide Y revealed using genetically modified animals. *Neuropeptides* 36(2–3), 182–193.

Tokuda, M., & Hatase, O. (1998). Regulation of neuronal plasticity in the central nervous system by phosphorylation and dephosphorylation. *Mol Neurobiol* 17, 137–156.

Uhl, G. R., Liu, Q. R., Walther, D., Hess, J., & Naiman, D. (2001). Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. *Am J Hum Genet* 69, 1290–1300.

Valdez, G. R., Sabino, V., & Koob, G. F. (2004). Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin releasing factor-2 receptor activation. *Alcohol Clin Exp Res* 28, 865–872.

Valverde, O., Mantamadiotis, T., Torrecilla, M., Ugedo, L., Pineda, J., Bleckmann, S., Gass, P., Kretz, O., Mitchell, J. M., Schutz, G., & Maldonado, R. (2004). Modulation of anxiety-like behaviors and morphine dependence in CREB-deficient mice. *Neuropsychopharmacology* 29, 1122–1133.

Valverius, P., Hoffman, P. L., & Tabakoff, B. (1989). Brain forskolin binding in mice dependent on and tolerant to ethanol. *Brain Res* 503, 38–43.

Walker, D. L., Toufexis, D. J., & Davis, M. (2003). Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. *Eur J Pharmacol* 463, 199–216.

Walters, C. L., & Blendy, J. A. (2001). Different requirements for cAMP response element binding protein in positive and negative reinforcing properties of drugs of abuse. *J Neurosci* 21, 9438–9444.

Walters, C. L., Kuo, Y. -C., & Blendy, J. A. (2003). Differential distribution of CREB in the mesolimbic dopamine reward pathway. *J Neurochem* 87, 1237–1244.

Wand, G. S., & Levine, M. (1991). Hormonal tolerance to ethanol is associated with decreased expression of the GTP-binding protein, Gs alpha and adenylate cyclase activity in ethanol treated LS mice. *Alcohol Clin Exp Res* 15, 705–710.

Wand, G., Levine, M., Zweifel, L., Schwindger, W., & Abel, T. (2001). The cAMP protein kinase A signal transduction pathway modulates ethanol consumption and sedative effects of ethanol. *J Neurosci* 21, 5297–5303.

Weiss, F., Lorang, M. T., Bloom, F. E., & Koob, G. F. (1993). Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. *J Pharmacol Exp Ther* 267, 250–258.

Williams, T. P., & Miller, B. D. (2003). Pharmacologic management of anxiety disorders in children and adolescents. *Curr Opin Pediatr* 15, 483–490.

Wilson, G. T. (1988). Alcohol and anxiety. *Behav Res Ther* 26, 369–381.

Wise, R. A. (1996). Neurobiology of addiction. *Curr Opin Neurobiol* 6(2), 243–251.

Woldbye, D. P. (1998). Antiepileptic effects of NPY on pentylenetetrazole seizures. *Regul Pept* 75–76, 279–282.

Woldbye, D. P., Ulrichsen, J., Haugbol, S., & Bolwig, T. G. (2002). Ethanol withdrawal in rats is attenuated by intracerebroventricular administration of neuropeptide Y. *Alcohol Alcohol* 37, 318–321.

Xing, J., Kornhauser, J. M., Xia, Z., Thiele, E. A., & Greenberg, M. E. (1998). Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. *Mol Cell Biol* 18, 1946–1955.

Yang, X., Diehl, A. M., & Wand, G. S. (1996). Ethanol exposure alters the phosphorylation of cyclic AMP responsive element binding protein and cyclic AMP responsive element binding activity in rat cerebellum. *J Pharmacol Exp Ther* 278, 338–346.

Yang, X., Horn, K., Baraban, J. M., & Wand, G. S. (1998a). Chronic ethanol administration decreases phosphorylation of cyclic AMP-response element binding protein in granule cells of rat cerebellum. *J Neurochem* 70, 224–232.

Yang, X., Horn, K., & Wand, G. S. (1998b). Chronic ethanol administration impairs phosphorylation of CREB and CRE binding activity in rat striatum. *Alcohol Clin Exp Res* 22, 382–390.

Yang, X., Oswald, L., & Wand, G. (2003). The cyclic AMP/protein kinase A signal transduction pathway modulates tolerance to sedative and hypothermic effects of ethanol. *Alcohol Clin Exp Res* 27, 1220–1225.

Yao, L., Arolfo, M. P., Dohrman, D. P., Jiang, Z., Fan, P., Fuchs, S., Janak, P. H., Gordon, A. S., & Diamond, I. (2002). Betagamma dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. *Cell* 109, 733–743.

Zahm, D. S. (1999). Functional-anatomical implications of the nucleus accumbens core and shell subterritories. *Ann N Y Acad Sci* 877, 113–128.

Zahm, D. S. (2000). An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. *Neurosci Biobehav Rev* 24, 85–105.

Zahm, D. S., & Brog, J. S. (1992). On the significance of subterritories in the “accumbens” part of the rat ventral striatum. *Neuroscience* 50, 751–767.

Zhang, H., & Pandey, S. C. (2003). Effects of PKA modulation on the expression of neuropeptide Y in rat amygdaloid structures during ethanol withdrawal. *Peptides* 24, 1397–1402.

Zocchi, A., Girlanda, E., Vanier, G., Sartori, I., Zanetti, L., Wildish, G. A., Lennon, M., Mugnaini, M., & Heidbreder, C. A. (2003). Dopamine responsiveness to drugs of abuse: a shell-core investigation in the nucleus accumbens of the mouse. *Synapse* 50, 293–302.
